Alterola Biotech Beta vs. Current Ratio
| ABTI Stock | USD 0.01 0 25.00% |
For Alterola Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Alterola Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Alterola Biotech utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Alterola Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Alterola Biotech over time as well as its relative position and ranking within its peers.
Alterola |
Alterola Biotech Current Ratio vs. Beta Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Alterola Biotech's current stock value. Our valuation model uses many indicators to compare Alterola Biotech value to that of its competitors to determine the firm's financial worth. Alterola Biotech is number one stock in beta category among its peers. It is rated below average in current ratio category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Alterola Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Alterola Biotech's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Alterola Current Ratio vs. Beta
Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Alterola Biotech |
| = | -6.65 |
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Alterola Biotech |
| = | 0.10 X |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Alterola Current Ratio Comparison
Alterola Biotech is currently under evaluation in current ratio category among its peers.
Beta Analysis
As returns on the market increase, returns on owning Alterola Biotech are expected to decrease by larger amounts. On the other hand, during market turmoil, Alterola Biotech is expected to outperform it.
Alterola Biotech Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Alterola Biotech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Alterola Biotech will eventually generate negative long term returns. The profitability progress is the general direction of Alterola Biotech's change in net profit over the period of time. It can combine multiple indicators of Alterola Biotech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Alterola Biotech, Inc., a pharmaceutical company, engages in the development of cannabinoid and cannabinoid-like molecules. It focuses on the development of regulated human and animal health pharmaceuticals and regulated food products production of active pharmaceutical ingredients and food-grade ingredients and formulation and drug delivery for improved bioavailability, solubility, and stability. Alterola Biotech is traded on OTC Exchange in the United States.
Alterola Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Alterola Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Alterola Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Alterola Biotech's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Alterola Biotech without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Odds Of Bankruptcy Now
Odds Of BankruptcyGet analysis of equity chance of financial distress in the next 2 years |
| All Next | Launch Module |
Use Investing Themes to Complement your Alterola Biotech position
In addition to having Alterola Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Pharmaceutical Products Thematic Idea Now
Pharmaceutical Products
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Pharmaceutical Products theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Pharmaceutical Products Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Alterola Pink Sheet
To fully project Alterola Biotech's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Alterola Biotech at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Alterola Biotech's income statement, its balance sheet, and the statement of cash flows.